Meeting Banner
Abstract #1020

A zinc-sensitive MRI contrast agent differentiates healthy from cancerous prostate in a transgenic prostate cancer model

Veronica Clavijo Jordan 1, Su-Tang Lo1, Christian Preihs1, Sara Chirayil1, Wen-Hong Li1, Neil M Rofsky1, and Dean Sherry1,2

1UT Southwestern Medical Center, Dallas, TX, United States, 2UT Dallas, Richardson, TX, United States

The prostate has the highest levels of Zn(II) in the organism and there are marked differences in content between the healthy, malignant, and benign hyperplastic prostate. Given that accurate differential diagnosis between these conditions is difficult non-invasively, we introduce prostate Zn(II) as a MRI imaging biomarker. In this work we use a Gd-based zinc sensor that can sensitively detect glucose-stimulated intracellular release of Zn(II) in the healthy, and malignant mouse prostate using a transgenic adenocarcinoma model.

This abstract and the presentation materials are available to members only; a login is required.

Join Here